Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > January 11, 2023
Daily News
January 11, 2023
- FPMAJ Chief Poised to Push Rethink of Price Revision Rules towards FY2024 Reform
January 11, 2023
- Kaken Snags Japan Rights to CymaBay Med for Primary Biliary Cholangitis
January 11, 2023
- Otsuka, Schrodinger in Neurology Drug Discovery Collaboration
January 11, 2023
- US FDA Accepts Rexulti sNDA for Alzheimer’s Agitation: Otsuka/Lundbeck
January 11, 2023
- Astellas to Test Selecta’s IgG Protease with Pompe Gene Therapy
January 11, 2023
- NeuroDerm’s Parkinson’s Med Hits Main Goal in PIII
January 11, 2023
- AnGes, miRaX Ink Option Pact for MicroRNA Research
January 11, 2023
- Forxiga Now Available for Heart Failure Regardless of LVEF
January 11, 2023
- AbbVie, Eisai to End Humira Copromotion in June
January 11, 2023
- Japan Ethical Drug Sales Up 2.1% in November: Crecon
January 11, 2023
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…